Noritaka Kudo, Shinji Kudoh, Akira Matsuo, Yamato Motooka, Takaaki Ito
{"title":"ZMYM3可能促进小细胞肺癌细胞增殖。","authors":"Noritaka Kudo, Shinji Kudoh, Akira Matsuo, Yamato Motooka, Takaaki Ito","doi":"10.1267/ahc.21-00012","DOIUrl":null,"url":null,"abstract":"<p><p>Zinc finger, myeloproliferative, and mental retardation-type containing 3 (ZMYM3) is a highly conserved protein among vertebrates. Although it promotes DNA repair and moderate histone acetylation, the other functions of ZMYM3 remain unclear. We herein examined the physiological functions of ZMYM3 in human lung cancer using a <i>ZMYM3</i>-knockdown small cell lung cancer (SCLC) cell line. <i>ZMYM3</i>-knockdown SCLC cells grew slowly and the Ki-67 labeling index was lower in <i>ZMYM3</i>-knockdown cells than in mock cells. The subcutaneous tumors that formed after xenotransplantation into immunodeficient mice were slightly smaller in the <i>ZMYM3</i>-knockdown group than in the mock group. Furthermore, public RNA-sequencing data analyses showed similar RNA profiles between <i>ZMYM3</i> and some cell proliferation markers. These results indicate that ZMYM3 promotes cell proliferation in human lung carcinomas, particularly SCLC.</p>","PeriodicalId":6888,"journal":{"name":"Acta Histochemica Et Cytochemica","volume":"54 5","pages":"143-153"},"PeriodicalIF":1.6000,"publicationDate":"2021-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/c5/21-00012.PMC8569135.pdf","citationCount":"0","resultStr":"{\"title\":\"ZMYM3 May Promote Cell Proliferation in Small Cell Lung Carcinoma.\",\"authors\":\"Noritaka Kudo, Shinji Kudoh, Akira Matsuo, Yamato Motooka, Takaaki Ito\",\"doi\":\"10.1267/ahc.21-00012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Zinc finger, myeloproliferative, and mental retardation-type containing 3 (ZMYM3) is a highly conserved protein among vertebrates. Although it promotes DNA repair and moderate histone acetylation, the other functions of ZMYM3 remain unclear. We herein examined the physiological functions of ZMYM3 in human lung cancer using a <i>ZMYM3</i>-knockdown small cell lung cancer (SCLC) cell line. <i>ZMYM3</i>-knockdown SCLC cells grew slowly and the Ki-67 labeling index was lower in <i>ZMYM3</i>-knockdown cells than in mock cells. The subcutaneous tumors that formed after xenotransplantation into immunodeficient mice were slightly smaller in the <i>ZMYM3</i>-knockdown group than in the mock group. Furthermore, public RNA-sequencing data analyses showed similar RNA profiles between <i>ZMYM3</i> and some cell proliferation markers. These results indicate that ZMYM3 promotes cell proliferation in human lung carcinomas, particularly SCLC.</p>\",\"PeriodicalId\":6888,\"journal\":{\"name\":\"Acta Histochemica Et Cytochemica\",\"volume\":\"54 5\",\"pages\":\"143-153\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2021-10-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/c5/21-00012.PMC8569135.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Histochemica Et Cytochemica\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1267/ahc.21-00012\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/10/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Histochemica Et Cytochemica","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1267/ahc.21-00012","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/2 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
ZMYM3 May Promote Cell Proliferation in Small Cell Lung Carcinoma.
Zinc finger, myeloproliferative, and mental retardation-type containing 3 (ZMYM3) is a highly conserved protein among vertebrates. Although it promotes DNA repair and moderate histone acetylation, the other functions of ZMYM3 remain unclear. We herein examined the physiological functions of ZMYM3 in human lung cancer using a ZMYM3-knockdown small cell lung cancer (SCLC) cell line. ZMYM3-knockdown SCLC cells grew slowly and the Ki-67 labeling index was lower in ZMYM3-knockdown cells than in mock cells. The subcutaneous tumors that formed after xenotransplantation into immunodeficient mice were slightly smaller in the ZMYM3-knockdown group than in the mock group. Furthermore, public RNA-sequencing data analyses showed similar RNA profiles between ZMYM3 and some cell proliferation markers. These results indicate that ZMYM3 promotes cell proliferation in human lung carcinomas, particularly SCLC.
期刊介绍:
Acta Histochemica et Cytochemica is the official online journal of the Japan Society of Histochemistry and Cytochemistry. It is intended primarily for rapid publication of concise, original articles in the fields of histochemistry and cytochemistry. Manuscripts oriented towards methodological subjects that contain significant technical advances in these fields are also welcome. Manuscripts in English are accepted from investigators in any country, whether or not they are members of the Japan Society of Histochemistry and Cytochemistry. Manuscripts should be original work that has not been previously published and is not being considered for publication elsewhere, with the exception of abstracts. Manuscripts with essentially the same content as a paper that has been published or accepted, or is under consideration for publication, will not be considered. All submitted papers will be peer-reviewed by at least two referees selected by an appropriate Associate Editor. Acceptance is based on scientific significance, originality, and clarity. When required, a revised manuscript should be submitted within 3 months, otherwise it will be considered to be a new submission. The Editor-in-Chief will make all final decisions regarding acceptance.